Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 122 (1), 102-110

Inactivation of 3-hydroxybutyrate Dehydrogenase Type 2 Promotes Proliferation and Metastasis of Nasopharyngeal Carcinoma by Iron Retention

Affiliations

Inactivation of 3-hydroxybutyrate Dehydrogenase Type 2 Promotes Proliferation and Metastasis of Nasopharyngeal Carcinoma by Iron Retention

Bo Li et al. Br J Cancer.

Abstract

Background: 3-Hydroxybutyrate dehydrogenase type 2 (BDH2) is known to catalyse a rate-limiting step in the biogenesis of the mammalian siderophore and regulate intracellular iron metabolism. Here we aim to explore the expression and possible function of BDH2 in nasopharyngeal carcinoma (NPC).

Methods: The transcription and protein expression of BDH2 in NPC were determined by both real-time RT-PCR and immunohistochemistry staining assays. Cell proliferation, migration and invasion were evaluated by MTT assay, wound-healing assay and Transwell assay, respectively. The profile of genes regulated by restoring BDH2 expression in NPC cells was analysed by cDNA microarray. The level of iron in NPC cells was detected by iron colorimetric assay.

Results: The expression of BDH2 was significantly downregulated in NPC. Ectopic expression of BDH2 inhibited NPC cell proliferation and colony formation. Meanwhile, BDH2 suppressed the migration and invasion of NPC cells by reversing the epithelial-mesenchymal transition (EMT). In addition, a higher level of BDH2 decreased the growth and metastasis of NPC cells via reducing intracellular iron level.

Conclusions: Our findings suggest that BDH2 may be a candidate tumour-suppressor gene in NPC. Decreasing intracellular iron could be an effective therapeutic approach for NPC.

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol., Biomarkers Prev. 2006;15:1765–1777. - PubMed
    1. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin. Otolaryngol. Allied Sci. 2001;26:82–92. - PubMed
    1. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 2007;9:1–24. - PubMed
    1. Yu KH, Leung SF, Tung SY, Zee B, Chua DT, Sze WM, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head & Neck. 2005;27:397–405. - PubMed
    1. Legendre C, Garcion E. Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol. Metab. 2015;26:322–331. - PubMed

LinkOut - more resources

Feedback